



# CONCORD DRUGS LIMITED

Admin. Off: H.No. : 3-11-1/1, Opp: Kamineni Hospital, L.B. Nagar, Hyderabad - 500 074 (Telangana) INDIA.  
Tel: (040)-24037763, Fax: (040)-24036379, E-mail: concorddrugsltd@gmail.com, web: www.concorddrugs.in

To,

Date: 30.05.2019

BSE Limited,  
P.J. Towers, Dalal Street,  
Mumbai - 400001

Dear Sir/Madam,

Sub: Outcome of Board meeting held on 30.05.2019

Ref: Scrip Code 538965

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Concord Drugs Limited held on Thursday, 30.05.2019 at 5:00 p.m. at the registered office of the company the following were considered and approved:

1. Audited financial results for the quarter and year ended 31.03.2019. **(Enclosed)**
2. Auditors Report along with Declaration as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for year ended 31.03.2019. **(Enclosed)**

The meeting concluded at 9:45 p.m.

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,  
For Concord Drugs Limited

S. Nagi Reddy  
Chairman  
DIN: 01764665



Encl: as above



# CONCORD DRUGS LIMITED

Admin. Off: H.No. : 3-11-1/1, Opp: Kamineni Hospital, L.B. Nagar, Hyderabad - 500 074 (Telangana) INDIA.  
Tel: (040)-24037763, Fax: (040)-24036379, E-mail: concorddrugsltd@gmail.com, web: www.concorddrugs.in

To,

Date: 30.05.2019

BSE Limited,  
P.J. Towers, Dalal Street,  
Mumbai - 400001

Dear Sir,

Sub: Declaration pursuant to regulation 33 (3) (d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015


I, S. Nagi Reddy, Chairman of Concord Drugs Limited hereby declare that, the statutory Auditors of the company, M/s. NG Rao & Associates Chartered Accountants have issued an Audit Report with unmodified/unqualified opinion on Audited Financial Results of the company for the quarter and year ended 31<sup>st</sup> March, 2019.

This declaration is issued in compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you.

Yours faithfully,  
For Concord Drugs Limited

S. Nagi Reddy  
S. Nagi Reddy  
Chairman  
DIN: 01764665



**STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2019**

[Rs. in Lakhs]


Particulars	Quarterly ended				
	31-Mar-19			31-Mar-18	
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
<b>I Revenue from Operations</b>					
a. Net sales from Operations	1,434.45	921.00	2,109.55	4,807.72	5,179.72
b. Other Operating Income	2.16	1.90	-	8.59	13.58
<b>II Other Income</b>			18.13		
<b>III Total Revenue (I+II)</b>	<b>1,436.61</b>	<b>922.90</b>	<b>2,127.68</b>	<b>4,816.31</b>	<b>5,193.30</b>
<b>IV Expenses</b>					
a. Cost of Material Consumed	1,342.94	625.37	2,020.46	3,913.85	4,650.18
b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	- 50.73	22.85	66.78	45.59	(320.38)
c. Employees Benefit Expenses	34.15	81.59	27.69	252.92	197.42
d. Finance Costs	38.98	39.90	63.90	159.30	188.40
e. Depreciation and Amortisation expense	7.35	54.86	68.18	171.18	240.14
f. Other expenses	37.55	92.78	19.43	229.50	173.68
<b>Total Expenses</b>	<b>1410.23</b>	<b>917.35</b>	<b>2266.44</b>	<b>4772.33</b>	<b>5129.44</b>
<b>Profit/ (Loss) before Exceptional item and tax (III-IV)</b>	<b>26.38</b>	<b>5.55</b>	<b>-138.76</b>	<b>43.98</b>	<b>63.86</b>
<b>V Exceptional Items</b>			-		-
<b>VI Profit/ (Loss) before tax (V-VI)</b>	<b>26.38</b>	<b>5.55</b>	<b>-138.76</b>	<b>43.98</b>	<b>63.86</b>
<b>VII Tax Expense:</b>	<b>5.86</b>	<b>1.87</b>	<b>(6.13)</b>	<b>3.27</b>	<b>31.45</b>
<b>VIII a. Current tax</b>	-3.50	4.84		11.72	37.58
<b>b. Deferred tax charge/credit</b>	9.36	-2.97	6.13	8.44	6.13
<b>IX Profit/ (Loss) for the period (VII-VIII)</b>	<b>20.52</b>	<b>3.68</b>	<b>-132.63</b>	<b>40.70</b>	<b>32.41</b>
<b>X Other Comprehensive Income</b>			-		-
Items that will not be reclassified to profit or loss			-		-
<b>Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)</b>	<b>20.52</b>	<b>3.68</b>	<b>-132.63</b>	<b>40.70</b>	<b>32.41</b>
<b>XI Paid-up equity share capital</b>	<b>786.18</b>	<b>786.18</b>	<b>786.18</b>	<b>786.18</b>	<b>786.18</b>
(Face value of the share- Rs. 10 each)					
<b>Other Equity</b>	<b>1,529.46</b>	<b>1,146.14</b>	<b>1,146.14</b>	<b>1,529.46</b>	<b>1,146.14</b>
<b>XII Earnings per share (of Rs. 10 each)</b>					
<b>XIII a. Basic (in Rs)</b>	0.26	0.05	1.69	0.52	0.41
<b>b. Diluted (in Rs)</b>	0.26	0.05	-1.69	0.52	0.41

Notes:	
1	The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under.
2	The above standalone financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on May 30, 2019
3	The company adopted the Indian Accounting standards (Ind AS) from 01.04.2017 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS- 34 "Interim Financial Reporting" prescribed under Section 133 of Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India.  Note: The figures for the quarter ended March 31, 2019 are balancing figures between the Audited figures of the full financial year ended 31, March 2019 & the published year to date figures upto 9 months ended Dec 31, 2018
4	Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.
5	The results are also available on the website of the Company <a href="http://www.genera.in">www.genera.in</a> .

Place: Hyderabad  
Date: May 30, 2019

By Order of the Board  
For Concord Drugs Limited

*S. Nagi Reddy*  
S Nagi Reddy  
Managing Director  
DIN: 01764665



**Concord Drugs Limited Survey No 249 , Brahmanapally Village Hayathnagar Manadal RR District, Pin - 501511, Telangana**

**Balance sheet as at 31, March 2019**

Particulars	Note	As At March 31, 2019	As at March 31, 2018
<b>ASSETS</b>			
<b>Non-current assets</b>			
(a) Property, plant and equipment	3	1,106.32	1,272.38
(b) Capital Work-in Progress	3	28.89	-
(b) Investment property	3	78.60	78.60
<b>Financial assets</b>			
(a) Loans & Advances	5	50.02	50.02
Other Non current assets	4	39.26	38.48
<b>Total Non - Current Assets</b>		<b>1,303.08</b>	<b>1,439.48</b>
<b>Current Assets</b>			
Inventories	7	1,864.15	1,861.94
<b>Financial assets</b>			
(a) Investments			-
(b) Trade receivables	6	4,843.47	7,117.23
(c) Cash and cash equivalents	8	15.89	4.08
(d) Bank balances other than (c) above	8	2.59	1.49
(e) Other Current Financial Assets	9	4.13	12.71
Other current assets	10	243.53	204.47
<b>Total Current assets</b>		<b>6,973.77</b>	<b>9,201.91</b>
<b>Total Assets</b>		<b>8,276.85</b>	<b>10,641.39</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
Equity share capital	11	786.18	786.18
Other equity	12	1,529.46	1,146.14
<b>Total Equity</b>		<b>2,315.63</b>	<b>1,932.32</b>
<b>Non-current liabilities</b>			
<b>Financial Liabilities</b>			
(a) Borrowings	13	68.97	340.85
(b) Trade payables			
Deferred tax liabilities, net	14	12.79	21.23
Provisions	15	217.23	214.36
Government Grants	13	54.13	61.75
<b>Total Non-current liabilities</b>		<b>353.13</b>	<b>638.19</b>
<b>Current liabilities</b>			
<b>Financial liabilities</b>			
(a) Borrowings	16	913.68	900.51
(b) Trade payables	17	4,263.73	6,636.83
(c) Other Current financial liabilities	18	-	121.06
Current tax liabilities, net	15	11.72	37.58
Other current liabilities	19	418.96	374.90
<b>Total Current liabilities</b>		<b>5,608.09</b>	<b>8,070.88</b>
<b>Total liabilities</b>		<b>5,961.22</b>	<b>8,709.07</b>
		<b>8,276.85</b>	<b>10,641.38</b>

For N.G Rao and Associates  
Chartered Accountants  
FRN- 009399S

S/d  
G. Nageswara Rao  
Partner  
Mno-207300

Place: Hyderabad  
Date: 30-05-2019

For Concord Drugs Limited

S/d  
S. Nagi Reddy  
Managing Director  
DIN:0001764665




**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF STAND ALONE FINANCIAL RESULTS**

**TO**  
**THE BOARD OF DIRECTORS**  
**CONCORD DRUGS LIMITED**

1. We have audited the accompanying Statement of Standalone Financial Results of CONCORD DRUGS LIMITED ("The company ") for the quarter ended March 31, 2019 ("the Statement "), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5,2016
2. This Statement is the responsibility of the Company's Management and is approved by the Board of Directors. The Statement, as it relates to the quarter ended March 31, 2019, has been compiled from the related interim condensed Standalone Financial Statements prepared in accordance with Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") and as it relates to the year ended March 31, 2019, has been compiled from the related annual standalone financial statements prepared under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such interim consolidated financial statements and annual consolidated financial statements.
3. We conducted our audit in accordance with the standards on Auditing issued by the Institute of Chartered Accounts of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial controls relevant to the company's preparation and fair presentation of the statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal financial controls. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence obtained by us, sufficient and appropriate to provide a basis for our audit opinion.



4. In our opinion and to the best of our information and according to the explanations given to us, the statements,
- is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. As modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016; and
  - gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the standalone profits and total comprehensive income for the period and other financial information of the Group for the quarter and year ended March 31, 2019.

**For NG Rao & Associates**

Chartered Accountants  
(FRNo. 009399S)



G.Nageswara Rao  
Partner  
(Membership No. 207300)

**UDIN: 19207300AAAABJ8666**